首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 156 毫秒
1.
目的;观察厄贝沙坦治疗老年原发性高血压的疗效,并与卡托普利比较。方法:选择60例住院老年原发性高血压病人,随机分为二组。治疗组用厄贝沙坦,开始75mg每日晨6:00一次口服,一用后血压未控制达标,增至150mg,共4周。对照组用卡托普利12.5mg,每8小时一次(8:00,12:00,20:00)一周后血压控制未达标。增长25mg,共4周。每组20例行动态血压监测。结果:厄贝沙坦组与卡托普利组总有效率为90%,与87%(P〉0.05)。动态血压监测夜间舒张压卡托普利组下降不显著,与厄贝沙坦组比较有非常显著意义(P〈0.01)。结论:厄贝沙坦治疗老年原发性高血压,疗效好且安全,降低夜间血压优于卡托普利。  相似文献   

2.
目的观察厄贝沙坦对原发性高血压患者的降压作用及对蛋白尿的影响。方法将72例轻中度原发性高血压伴蛋白尿患者于停药1周后给予厄贝沙坦,每次150mg,每日1次,共治疗3个月。同时观察患者治疗前后血压、24h尿蛋白定量、肾功能及血13,微球蛋白的变化。结果治疗3个月后,收缩压由治疗前的(151.0±13.7)mmHg降至(130.7±15.8)mmHg,差异有统计学意义(t=2.51,P〈0.05);舒张压由治疗前的(94.9±10.6)mmHg降至(84.5±6.3)mmHg,差异有统计学意义(t=2.95,P〈0.01)。24h尿蛋白定量由(1.49±0.59)g降至(0.64±0.43)g,与治疗前相比差异有统计学意义(t=2.83,P〈0.01);p2微球蛋白由(3.22±2.71)mg/L降至(2.13±1.82)mg/L,与治疗前相比差异有统计学意义(t=2.57,P〈0.05)。结论厄贝沙坦治疗原发性高血压患者降压效果确切,能显著降低尿蛋白,改善肾功能。  相似文献   

3.
厄贝沙坦治疗原发性高血压疗效观察   总被引:1,自引:0,他引:1       下载免费PDF全文
目的:评价厄贝沙坦治疗原发性高血压(EH)的疗效及安全性,并与依那普利比较。方法:96例1、2级EH患者,随机分为厄贝沙坦治疗组(A组)及依那普利治疗组(B组)各48例,分别给予厄贝沙坦0.15g/d和依那普利10mg/d,每2周随访并调整剂量、记录不良反应至8周;服药前行相关检查。结果:A组总有效率为79.2%,B组总有效率为77.1%,2组比较无显著差异;干咳等副作用发生率A组为4.16%,B组为20.83%,有显著性差异。结论:厄贝沙坦治疗EH疗效确切,且耐受性好,干咳等副作用明显低于依那普利。  相似文献   

4.
目的:分析并研究单独使用厄贝沙坦与联合依那普利对原发性高血压进行治疗的效果。方法:本研究所有选择的研究对象均来自本院在2017年1月至2018年1月收治的原发性高血压患者,本研究选择102例患者作为本研究的研究对象,将本研究所有患者划分为观察组和对照组,每组患者51例。对照组患者选择采用厄贝沙坦进行治疗,观察组选择采用厄贝沙坦联合依那普利进行治疗,对两组患者的治疗效果进行比较。结果:评价两组患者治疗结束以后的治疗总有效率,观察组患者的治疗有效率明显高于对照组,两组之间存在差异性,P<0.05,具有统计学意义。结论:厄贝沙坦联合依那普利对原发性高血压进行治疗可以收获良好的效果,能有效促进患者临床病症的恢复,提升患者治疗的总有效率,是一种值得推广应用的治疗方法。  相似文献   

5.
选取2011年4月~2013年6月我院收治的原发性高血压患者152例,随机分为观察组及对照组,均行常规治疗及口服氨氯地平,观察组患者再加服厄贝沙坦。两组患者均治疗8w,并观察治疗效果。结果治疗前两组患者血压比较差异无统计学意义(P0.05),治疗后两组患者血压均有所改善,但观察组改善情况显著性优于对照组(P0.05);治疗后,观察组中,显效34例,有效33例,无效9例,总有效率88.2%;对照组中,显效18例,有效42例,无效16例,总有效率78.9%。观察组总有效率显著性高于对照组(P0.05)。厄贝沙坦治疗老年原发性高血压的临床效果显著,可有效改善患者血压,并建议在临床治疗中推广应用。  相似文献   

6.
目的:观察厄贝沙坦联合苯磺酸氨氯地平治疗原发性高血压的疗效。方法选择2010年1月~2013年1月180例原发性高血压患者,随机分为厄贝沙坦组(A组)、苯磺酸氨氯地平组(B组)和厄贝沙坦联合苯磺酸氨氯地平组(C 组)各60例。 A 组给予厄贝沙坦150mg,1次/d,B 组给予苯磺酸氨氯地平5mg,2次/d,C 组给予厄贝沙坦150mg,1次/d,苯磺酸氨氯地平5mg,2次/d。疗程均为8w。治疗前后分别测量血压,检测血电解质、肝肾功能、12导联心电图等,观察、记录药物的不良反应。结果三组治疗前后的收缩压、舒张压均有明显下降,总有效率A、B两组比较无明显统计学差异,C组与A、B两组比较有显著性差异(P<0.05)。结论厄贝沙坦联合苯磺酸氨氯地平治疗原发性高血压较各自单用临床疗效明显,安全性高,值得临床推广运用。  相似文献   

7.
目的 观察厄贝沙坦和氢氯噻嗪联合治疗原发性高血压的疗效及安全性。方法 56例轻中度原发性高血压患者,停药两周后,随机分为两组:联合治疗组(厄贝沙坦150mg/d及氢氯噻嗪12.5mg/d)。单药治疗组((厄贝沙坦150mg/d),每组28例,疗程8周。在治疗第1、2、4、8周末记录血压、心率及不良反应。结果 联合治疗组总有效率92.9%;单药治疗组总有效率78.5%,两组比较有统计学差异(P〈0.01)。结论 厄贝沙坦和氢氯噻嗪联用能有效控制血压,用药简单、方便、不良反应少,是值得临床推广的联合降压方案。  相似文献   

8.
目的探讨厄贝沙坦联合左旋氨氯地平治疗原发性高血压的临床疗效。方法选取186例原发性高血压患者作为研究对象,随机分成治疗组和对照组各93例,两组患者均给予厄贝沙坦治疗,治疗组在此基础上再给予左旋氨氯地平治疗,治疗时间为8w。比较两组患者在治疗前后血压及治疗的有效率等情况。结果相比治疗前,两组患者的舒张压(DBP)和收缩压(SBP)均有明显下降,治疗后两组之间收缩压结果比较差异具有统计学意义(P0.05);治疗8w后,治疗组和对照组治疗总有效率分别为96.77%和88.17%,两组比较,差异具有统计学意义(P0.05)。结论相比单纯应用厄贝沙坦治疗老年人原发性高血压,厄贝沙坦联合左旋氨氯地平治疗的临床疗效显著且无明显不良反应,安全性高,值得临床推广应用。  相似文献   

9.
选择2008年3月~2012年5月我院收治的原发性高血压患者150例,随机分为两组,治疗组75例采用氨氯地平联合厄贝沙坦治疗;对照组75例采用氨氯地平治疗,治疗8w后,观察两组的疗效。结果两组患者的收缩压和舒张压均有下降,治疗组总有效率为90.7%,对照组总有效率为69.3%,治疗组总有效率高于对照组(P<0.05)。氨氯地平联合厄贝沙坦治疗原发性高血压优于单用氨氯地平组,且安全性良好。  相似文献   

10.
目的探讨厄贝沙坦治疗轻中度原发性高血压的疗效及不良反应。方法将80例轻中度原发性高血压患者分为2组,厄贝沙坦组40例,采用厄贝沙坦150 mg,口服,1次/d;依那普利组40例,采用依那普利10 mg,口服,2次/d,6周为1疗程。比较2组治疗前后疗效和不良反应。结果厄贝沙坦组与依那普利组的总有效率分别为97.5%和85.0%,2组比较差异有统计学意义(P〈0.05)。依那普利组有4例发生干咳而停药。结论厄贝沙坦治疗原发性高血压安全、有效。  相似文献   

11.
孙均 《临床急诊杂志》2012,(5):330-331,334
目的:观察厄贝沙坦和卡托普利联合治疗高血压并发微量白蛋白尿患者的降压效果和减少尿微量白蛋白效果。方法:采用随机分组对照法将84例原发性高血压病并发微量白蛋白尿患者分为三组:厄贝沙坦治疗组26例;卡托普利治疗组28例;厄贝沙坦联合卡托普利治疗组30例。观察4周,收集血压、尿素氮、尿微量白蛋白等指标。结果:三组均能显著降低血压和尿微量白蛋白,但联合治疗组较任一单用组更显著减少了尿微量白蛋白(P<0.05)。结论:厄贝沙坦与卡托普利联合治疗高血压并发微量蛋白尿患者不但能有效的控制高血压还具有显著的肾功能保护作用。  相似文献   

12.
目的探讨厄贝沙坦氢氯噻嗪片治疗高血压的临床效果。方法选取我院收治的200例高血压患者作为研究对象,采用随机数字表法分为参照组(100例,厄贝沙坦片)和试验组(100例,厄贝沙坦氢氯噻嗪片)。比较两组患者的治疗效果。结果治疗后,两组的收缩压、舒张压及CRP水平均降低,且试验组明显低于参照组(P<0.05)。治疗后,两组的血液流变学指标比较,差异均无统计学意义(P>0.05)。试验组的治疗总有效率明显高于参照组(P<0.05)。两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论厄贝沙坦氢氯噻嗪片治疗高血压的临床效果显著,具有良好的降压及抗炎效果,且不会对血液流变学指标产生明显影响,安全性较高。  相似文献   

13.
田刚  辛建文  卢群 《临床荟萃》2010,25(8):647-650
目的 观察螺内酯和厄贝沙坦单用或联用对肥胖高血压患者血清脂联素水平及大动脉弹性的影响.方法 入选92例肥胖原发性高血压患者,随机分为螺内酯组(20 mg/d,n=26),厄贝沙坦组(150 mg/d,n=31)及联合组(螺内酯20 mg/d+厄贝沙坦150 mg/d,n=35)治疗24周.测定各组治疗前后的体质量指数(BMI)、腰臀比值(WHR)、收缩压(SBP)、舒张压(DBP)和脉压(PP),采用放射免疫法检测血清脂联素水平,应用CVProfilor DO-2020型动脉功能检测仪检测大动脉弹性指数(C1)和小动脉弹性指数(C2).结果 与治疗前比较,药物治疗24周后,3组SBP、DBP、PP值均显著下降(P<0.05或<0.01),分别为螺内酯组SBP(144.0±9.4)mmHg vs(131.0±8.7)mmHg,DBP(88.4±10.4)mmHg vs(78.1±7.5)mmHg,PP(58.4±27.3)mmHg vs(54.3±9.2)mmHg;厄贝沙坦组SBP(146.0±9.4)mmHg vs(126.0±8.9)mmHg,DBP(85.4±10.1)mmHg vs(74.2±6.9)mmHg,PP(56.1±27.3)mmHg vs(49.9±8.8)mmHg;联合组SBP(145.0±9.3)mmHg vs(117.0±9.7)mmHg,DBP(87.8±10.7)mmHg vs(68.3±6.4)mmHg,PP(57.7±22.5)mmHg vs(45.4±8.7)mmHg.药物治疗24周后,SBP、DBP、PP值降低幅度联合组均分别大于螺内酯和厄贝沙坦单药治疗组(P<0.01或<0.05).厄贝沙坦组血清脂联素水平的中住数和四分位间距[M(QR)]为[[5.6(2.31~8.21)]mg/L vs 12.8(2.48~20.12)]mg/L,动脉弹性功能指数C1[13.7(5.89~19.02)]ml/mmHg × 10 vs[10.3(4.52~17.02)]ml/mmHg×10,C2[5.1(1.38~7.98)]ml/mmHg ×100 vs[3.4(1.37~6.05)]ml/mmHg 1 100,均明显高于螺内酯组(均P<0.05);联合组血清脂联素水平[15.3(5.62~20.23)]mg/L vs[5.4(2.13~8.16)]ml/L,动脉弹性功能指数C1[14.3(7.81~12.98)]ml/mmHg×10 vs[10.2(5.02~19.10)]ml/mmHg×10,C2[5.9(1.62~8.20)]ml/mmHg×100 vs[3.5(1.39~5.91)]ml/mmHg×100则分别显著高于螺内酯和厄贝沙坦组(P<0.01或<0.05).结论 螺内酯和厄贝沙坦联合应用提高肥胖高血压患者血清脂联素水平和改善动脉弹性的作用明显优于单药应用组.  相似文献   

14.
目的研究血栓素B2(TXB2)及血浆内皮素-1(ET-1)在急性呼吸窘迫综合征(ARDS)患者中表达差异。方法选自我院收入的ARDS患者共45例,另选30例健康人群作为健康对照,ARDS组患者分别在确诊后1d、4d和7d清晨三个不同时点各抽取空腹静脉血5ml,健康对照组同样于清晨空腹抽静脉血5ml,采用放射免疫法测定血浆中的TXB2及血浆ET-1,所测结果两组进行比较。结果确诊后1d、4d和7d的血浆ET-1表达水平显著高于健康对照组(P<0.05)。ARDS组患者的TXB2于确诊后1d、4d和7d表达水平显著高于健康对照组(P<0.05)。确诊后7dTXB2表达水平达到最高值,显著高于1d和4d两个时点(P<0.05)。结论 ARDS患者血浆中TXB2及血浆ET-1水平明显增高,TXB2及血浆ET-1可能参与了ARDS发生的病理生理过程,其含量变化与疾病的发生发展可能存在关系,为诊断ARDS提供了一个有价值的指标。  相似文献   

15.
BACKGROUND: Endothelin-1 (ET-1) is an endogenous vasoconstrictive peptide hormone and asymmetric dimethylarginine (ADMA) acts as an endogenous inhibitor of nitric oxide synthase. We hypothesized that both could contribute to pulmonary hypertension in patients with left-to-right shunt after intracardiac repair. PATIENTS AND METHODS: We prospectively analyzed ET-1 and ADMA plasma levels in 31 patients (m = 16; f = 15) at an age of 0.6 [0.2-27] years (median [range]) with left-to-right shunt (ASD II: n = 12; VSD: n = 11; AVSD: n = 8) presenting with a Qp/Qs of 2.7 [1.4-6.3] and a pulmonary arterial mean pressure (PAP) of 23 [13-57] mmHg. Blood specimens were taken prior to cardiopulmonary bypass (CPB), after weaning from CPB and at 3, 6, 12 and 24 h after CPB. RESULTS: 12/31 patients were found to have pulmonary hypertension prior to intracardiac repair and 11/12 patients showed persistent pulmonary hypertension during the first 24 h after CPB. Patients with pulmonary hypertension at 12 h after CPB showed significant higher plasma ET-1 compared with patients with normal PAP (1.4 [0-7.9] versus 0.5 [0-2.5] pg/ml; P = 0.048 (Mann-Whitney)). Plasma ADMA decreased from 1.3 [0.75-2.3] micromol/l before CPB to 0.7 [0.4-2.1] micromol/l at 12 h (P < 0.05). However patients with pulmonary hypertension did not show different ADMA plasma levels. CONCLUSIONS: Increased plasma ET-1 but not inhibition of nitric oxide synthase by ADMA is associated with pulmonary hypertension after intracardiac repair.  相似文献   

16.
目的:探讨妊娠高血压患者血清淀粉样蛋白 A(SAA)、血浆内皮素1(ET-1)和一氧化氮(NO)水平变化及其相互关系。方法选择妊娠高血压患者65例,按照疾病严重程度分为单纯妊娠高血压24例,子痫前期轻度19例和子痫前期重度22例。健康孕妇30例和健康体检的妇女20例分别为正常妊娠组和健康对照组。检测各组 SAA, ET-1和 NO 水平,分析妊娠高血压患者 SAA,ET-1和 NO 水平与疾病严重程度之间的相关性。结果①与健康对照组比较,妊娠高血压组和正常妊娠组的 SAA 和 ET-1水平明显增高,妊娠高血压组明显高于正常妊娠组(P <0.01);妊娠高血压组和正常妊娠组 NO 水平明显降低,妊娠高血压组明显低于正常妊娠组(P <0.01)。②与单纯妊娠高血压组比较,子痫前期轻度和子痫前期重度组的 SAA 和 ET-1水平明显增高,子痫前期重度组高于子痫前期轻度组(P <0.01);子痫前期轻度和子痫前期重度组 NO 水平明显降低,子痫前期重度组低于子痫前期轻度组(P <0.05)。③妊娠高血压患者的 SAA 水平与 ET-1水平呈正相关(r =0.876,P <0.05),而与 NO 水平呈负相关(r =-0.761,P <0.05)。结论妊娠高血压患者存在内皮细胞功能紊乱,SAA,ET-1和 NO 参与了妊娠高血压的发生发展,测定SAA,ET-1和 NO 水平有助于妊娠高血压的早期诊断。  相似文献   

17.
To understand better the role of endothelin-1 (ET-1) in the pathogenesis of primary Raynaud's phenomenon (PRP), we investigated the basal ET-1 plasma levels and changes after whole-body cooling in healthy women and those with PRP. The study was performed as an open parallel-group comparison during the month of February. The Raynaud group included 21 female patients (mean age 45·3 years, range 21–57 years) who had had disabling Raynaud's phenomenon for a mean period of 17 years (range 2–26 years). The control group consisted of 25 healthy women (mean age 43·6 years, range 27–56 years). Plasma levels of ET-1 were measured on two separate occasions: once after 30 min of rest at room temperature and after 40 min of whole-body cooling. There were no significant differences in baseline plasma ET-1 levels between the two groups of women. The plasma ET-1 levels increased significantly in the PRP group after cold exposure (mean difference 0·11 pmol l?1, 95% CI 0·005–0·214, P = 0·012). In contrast, the levels of plasma ET-1 in the control group did not change significantly after cold provocation. In conclusion, no differences in plasma basal levels of ET-1 were observed between the two groups. However, women suffering from Raynaud's phenomenon responded with a slight but significant elevation in plasma levels of ET-1 after whole-body cooling, whereas the healthy control subjects did not. The results from the present study confirm previous observations that endothelial dysfunction may be of aetiological importance in PRP.  相似文献   

18.
高血压心脏病血浆神经肽Y的变化及其临床意义   总被引:15,自引:0,他引:15  
目的:探讨神经肽Y(NPY)在高血压心脏病(HHD)发生和发展中的意义。方法:对HHD及原发性高血压Ⅰ期(EH)患者分别给予肼苯达嗪(HYD)和培哚普利(PER)治疗,用放射免疫分析法测定HHD和EH患者治疗前后血浆NPY的浓度。结果:HHD患者血浆NPY浓度〔(163.65±32.48)ng/L〕明显高于EH组〔(98.09±16.77)ng/L〕,且血浆NPY的浓度随心功能损害程度加重而上升(F=24.95,P<0.01);EH患者经PER治疗后血浆NPY浓度下降,而HYD则无此作用;对HHD患者,PER在纠正心力衰竭的同时使血浆NPY的浓度下降更明显。结论:NPY可能在HHD发生和发展过程中起到一定的作用;NPY作为一项监测指标,可能对判断高血压心脏病患者的预后有一定的意义  相似文献   

19.
BACKGROUND AND AIMS: There were controversies as to whether endothelin-1 is released after coronary angioplasty. We sought to determine whether endothelin-1 is released after coronary angioplasty and whether oestrogen administration can affect coronary vasomotor tone by reducing endothelin-1 concentrations. METHODS: The study was designed to prospectively investigate 24 consecutive patients scheduled for elective coronary angioplasty. Patients were randomized into two groups according to whether they did not (group 1, n = 12) or did (group 2, n = 12) have intracoronary treatment with oestrogen. Quantitative coronary angiography was monitored at baseline, immediately after successful angioplasty, and 15 min after the last deflation. Blood samples for measuring the levels of endothelin-1 were drawn from the ascending aorta and the coronary sinus simultaneously before angioplasty and 15 min after balloon dilatation. RESULTS: The diameters of the coronary artery at the dilated segments were significantly reduced 15 min after dilation compared with those immediately after dilation in group 1 from 3.20 +/- 0.22 to 2.30 +/- 0.23 mm (P < 0.001), respectively. The vasoconstriction was significantly blunted in group 2. The endothelin-1 levels from the coronary sinus rose significantly, by 29%, 15 min after angioplasty in group 1, which was attenuated after administering oestrogen. Significant correlation was found between the changes of coronary vasomotion of the dilated segment and endothelin-1 levels (r = 0.70, P = 0.01). CONCLUSION: Endothelin-1 is released into the coronary circulation after angioplasty, and this vasoactive substance may contribute to the occurrence of vasoconstriction. The vasoconstriction is attenuated by oestrogen by reducing the endothelin-1 levels. This finding provided a new strategy to treat coronary vasoconstriction after angioplasty.  相似文献   

20.
Plasma endothelin (ET-1) and renal endothelin are two distinct functional systems involved in maintaining blood volume. To investigate whether plasma and renal ET-1 participate in the cardiovascular response to exercise-induced hypovolaemia, we studied changes in plasma and urinary ET-1 in healthy non-professional athletes after 2 h of jogging performed both without and with drinking isotonic fluids. After the run, which caused a 13% plasma volume (PV) reduction, plasma and renal ET-1 (+117% and +118%) increased significantly (all P  < 0.01). Fluid loss restitution during the run significantly attenuated either the PV contraction (−1.2%) and plasma and renal ET-1 increase (+2 and +3%). At multiple regression analysis changes in AVP plasma concentration, and not in PRA or PV per se , were significantly related to ET-1 changes both in plasma and urine. The present findings indicate that both plasma and renal ET-1 participate in the cardiovascular response to hypovolaemia induced by long-lasting, dynamic exercise.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号